Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M19.8Revenue (TTM) $M0.1Net Margin (%)-9,190.3Altman Z-Score-18.1
Enterprise Value $M11.3EPS (TTM) $-0.5Operating Margin %-12,196.1Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.9Pre-tax Margin (%)-9,190.3Higher ROA y-yY
Price/Book1.110-y EBITDA Growth Rate %-11.2Quick Ratio3.8Cash flow > EarningsY
Price/Sales1605-y EBITDA Growth Rate %-4.0Current Ratio3.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-41.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-49.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M24.1ROIC % (ttm)-119.8Gross Margin Increase y-yN

Gurus Latest Trades with HEB

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

HEB is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


HEB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Equels Thomas K.CEO,President 2016-11-01Buy10,000$1-18view
Equels Thomas K.CEO, President 2016-07-08Buy48,000$0.12583.33view
Equels Thomas K.CEO,President 2016-07-01Buy171,000$0.12583.33view
Equels Thomas K.CEO,Pres,Exec Vice Chairman 2016-03-18Buy30,000$0.13530.77view
Equels Thomas K.CEO,Pres,Exec Vice Chairman 2016-03-11Buy40,000$0.16412.5view
Equels Thomas K.CEO,Pres,Exec Vice Chairman 2016-03-11Buy40,000$0.16412.5view
Equels Thomas K.CEO,Pres,Exec Vice Chairman 2016-03-10Buy30,000$0.16412.5view
Equels Thomas K.CEO,Pres,Exec Vice Chairman 2016-03-10Buy30,000$0.16412.5view
CARTER WILLIAM ACEO, 10% Owner 2015-08-20Buy25,000$0.18355.56view
CARTER WILLIAM ACEO, 10% Owner 2015-08-18Buy25,000$0.18355.56view

Quarterly/Annual Reports about HEB:

News about HEB:

Articles On GuruFocus.com
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-K/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CEO Sells Highlight: Hemispherx Biopharma Inc, ADESA Inc, Entergy Corp, and Danaher Corp. Aug 15 2010 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Aug 06 2010 
Hemispherx Biopharma Inc (HEB) CEO William A Carter buys 500,000 Shares Jul 01 2010 
Weekly CFO Buys Highlight: Wireless Telecom Group, ValueVision Media, American River Bankshares, Hem Dec 12 2009 
Hemispherx Biopharma Inc (HEB) CFO Charles Thomas Iii Bernhardt buys 2,000 Shares Dec 08 2009 

More From Other Websites
Crystal Research Associates, LLC Issues Executive Informational Overview on Hemispherx Biopharma,... Dec 01 2016
ETFs with exposure to Hemispherx Biopharma, Inc. : November 23, 2016 Nov 23 2016
Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016 Nov 21 2016
Hemispherx Biopharma to Present at the 9th Annual LD Micro Main Event Nov 21 2016
Hemispherx 3Q Loss $2.9M or 13 Cents a Share (HEB) Nov 16 2016
Hemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ended... Nov 14 2016
Hemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ended... Nov 14 2016
Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15,... Nov 10 2016
Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15,... Nov 10 2016
Hemispherx Biopharma Featured in Corporate America News Magazine Special Report "Capturing the Power... Nov 08 2016
Hemispherx Biopharma Featured in Corporate America News Magazine Special Report “Capturing the... Nov 08 2016
Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen®... Oct 31 2016
Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen®... Oct 31 2016
Hemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer Milestone Oct 19 2016
Hemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer Milestone Oct 19 2016
Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case Sep 22 2016
Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case Sep 22 2016
Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards Sep 19 2016
Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards Sep 19 2016
Hemispherx Biopharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference Sep 06 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)